Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shenzhen Salubris Invests $10 Million in Viracta; Signs $58 Million Deal for Cancer Drug

publication date: Dec 4, 2018

Shenzhen Salubris Pharma invested $10 million in Viracta Therapeutics of San Diego. Salubris also acquired greater China rights to Viracta's clinical-stage treatment for Epstein Barr Virus (EBV)-associated lymphomas in a deal that includes $58 million in development milestones, plus unspecified commercial milestones and tiered royalties. The treatment is the first targeted, oral therapy for EBV-associated malignancies. It combines Viracta’s nanatinostat (VRx-3996) plus an antiviral and may treat a range of cancers associated with viruses. More details....

Stock Symbol: (SZE: 002294)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020